Published in Crit Rev Oncol Hematol on June 28, 2005
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer (2006) 1.03
Primary Malignant Vaginal Melanoma - Case Report and Review of the Literature. Geburtshilfe Frauenheilkd (2012) 0.76
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol (2004) 1.83
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol (2009) 1.75
Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle (2010) 1.73
Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer (2010) 1.66
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med (2012) 1.60
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol (2010) 1.45
Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol (2004) 1.41
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9). Oncology (2014) 1.41
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res (2006) 1.37
HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol (2009) 1.35
X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc Natl Acad Sci U S A (2003) 1.30
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. Cancer Cell (2004) 1.27
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis (2008) 1.17
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep (2008) 1.16
Human melanoma metastases express functional CXCR4. Clin Cancer Res (2006) 1.15
NF-κB as potential target in the treatment of melanoma. J Transl Med (2012) 1.14
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep (2012) 1.09
CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg (2011) 1.07
Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Biogerontology (2010) 1.07
Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res (2005) 1.06
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06
Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res (2008) 1.06
Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother (2012) 1.03
Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw (2010) 1.02
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer (2009) 1.02
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia (2012) 0.99
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother (2004) 0.99
Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer (2007) 0.98
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol (2003) 0.97
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer (2005) 0.97
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med (2012) 0.97
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer (2006) 0.96
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med (2014) 0.95
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med (2013) 0.95
Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med (2013) 0.94
Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer (2005) 0.94
Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology (2006) 0.94
Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta (2011) 0.94
Oxidative stress in Fanconi anaemia: from cells and molecules towards prospects in clinical management. Biol Chem (2012) 0.94
Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol (2012) 0.93
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93
Human Cytokinome: a new challenge for systems biology. Bioinformation (2010) 0.93
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett (2008) 0.93
Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One (2013) 0.92
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med (2013) 0.92
Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One (2012) 0.91
Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw (2010) 0.91
High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. J Cell Physiol (2014) 0.91
HMGA1 protein expression in familial breast carcinoma patients. Eur J Cancer (2009) 0.91
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother (2007) 0.91
Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapy. Onkologie (2007) 0.91
Overexpression of h-prune in breast cancer is correlated with advanced disease status. Clin Cancer Res (2005) 0.90
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med (2012) 0.90
In vivo prooxidant state in Werner syndrome (WS): results from three WS patients and two WS heterozygotes. Free Radic Res (2005) 0.90
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population. BMC Cancer (2009) 0.90
CASC2a gene is down-regulated in endometrial cancer. Anticancer Res (2007) 0.90
High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer (2003) 0.89